You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

PANRETIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Panretin, and when can generic versions of Panretin launch?

Panretin is a drug marketed by Concordia and is included in one NDA.

The generic ingredient in PANRETIN is alitretinoin. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the alitretinoin profile page.

US Patents and Regulatory Information for PANRETIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Concordia PANRETIN alitretinoin GEL;TOPICAL 020886-001 Feb 2, 1999 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for PANRETIN

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Eisai GmbH Panretin alitretinoin EMEA/H/C/000279
Panretin gel is indicated for the topical treatment of cutaneous lesions in patients with acquired-immune-deficiency-syndrome (AIDS)-related Kaposi's sarcoma (KS) when:lesions are not ulcerated or lymphoedematous, and;treatment of visceral KS is not required, and;lesions are not responding to systemic antiretroviral therapy, and;radiotherapy or chemotherapy are not appropriate.
Withdrawn no no no 2000-10-11
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for PANRETIN

See the table below for patents covering PANRETIN around the world.

Country Patent Number Title Estimated Expiration
Netherlands 300043 ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 9311755 ⤷  Try a Trial
Spain 2066750 ⤷  Try a Trial
Japan 4001618 ⤷  Try a Trial
Australia 3421893 ⤷  Try a Trial
Austria 439341 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for PANRETIN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0617614 C300043 Netherlands ⤷  Try a Trial PRODUCT NAME: ALITRETINOIN; NAT. REGISTRATION NO/DATE: EU/1/00/149/001 20001011; FIRST REGISTRATION: EU/1/00/149/001 20001011
0617614 SPC/GB01/014 United Kingdom ⤷  Try a Trial PRODUCT NAME: ALITRETINOIN; REGISTERED: UK EU/1/00/149/001 20001018
0617614 11/2001 Austria ⤷  Try a Trial PRODUCT NAME: ALITRETINOIN; REGISTRATION NO/DATE: EU/1/00/149/001 20001011
0617614 2001/009 Ireland ⤷  Try a Trial PRODUCT NAME: PANRETIN-ALITRETINOIN
0617614 CA 2001 00012 Denmark ⤷  Try a Trial
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.